108 filings
Page 2 of 6
8-K
k4nrfi
8 Sep 21
AGTC is Excited to Announce Seasoned Healthcare Financial and Operations Executive Jonathan I. Lieber as their new Chief Financial Officer
9:23am
8-K
8j4563qlsp
18 Aug 21
AGTC Appoints Ophthalmology and Retinal Disease Specialist and Industry R&D Veteran Yehia Hashad, MD to its Board of Directors
8:04am
8-K
3w624tb9mnxf
30 Jul 21
Departure of Directors or Certain Officers
4:39pm
8-K
baz3u73 q7
24 Jun 21
AGTC Reports 12-Month Data from its Ongoing Phase 1/2 Achromatopsia
7:16am
8-K
u9moqh3msp pzdp4legt
21 Jun 21
Departure of Directors or Certain Officers
4:27pm
8-K
ahghx
17 May 21
Results of Operations and Financial Condition
4:11pm
8-K
36omhhm0
6 May 21
AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinical Trial
9:20am
8-K
6k9e9
26 Apr 21
AGTC Announces Departure of Chief Scientific Officer
4:36pm
8-K
qrw9mnovo3jtjo5 84
2 Apr 21
Other Events
5:12pm
8-K
v1s8pbgqt6oa9pcw2a
11 Feb 21
AGTC Announces Financial Results and Business Update for the Quarter Ended Provide Skyline trial results from the 12-month data in 3Q 2022; and
7:20am
8-K
zuub9u 7qxr2n9vrq4mh
1 Feb 21
Regulation FD Disclosure
4:08pm
8-K
9w31s
29 Jan 21
AGTC Announces Proposed Public Offering of Common Stock and Warrants
4:22pm
8-K
zbt676
27 Jan 21
AGTC Announces First Reported Improvements in Visual Sensitivity for Achromatopsia (ACHM) patients from its Ongoing Clinical Trials
4:29pm
8-K
xguji
23 Dec 20
Regulation FD Disclosure
4:18pm
8-K
28yu2vt7op xgwani4
18 Dec 20
Submission of Matters to a Vote of Security Holders
4:12pm
8-K
ldpoe 9v88l
16 Nov 20
AGTC Announces Financial Results and Business Update for the Quarter Ended
4:14pm
8-K
qfqzha7etkodm1wwz
17 Sep 20
Departure of Directors or Certain Officers
4:09pm
8-K
szrbgh ivj7d
9 Sep 20
Results of Operations and Financial Condition
7:15am
8-K
3yrq7nar
11 Aug 20
Regulation FD Disclosure
6:08am
8-K
191ujecxbeae
7 Aug 20
Departure of Directors or Certain Officers
4:27pm